A Phase 1a/1b Study of LY3405105 Administered to Patients with Advanced Solid Tumors
Anus | Bones and Joints | Brain and Nervous System | Colon | Corpus Uteri | Esophagus | Eye and Orbit | Kidney | Larynx | Lip, Oral Cavity and Pharynx | Liver | Lung | Melanoma, skin | Other Digestive Organ | Other Endocrine System | Other Female Genital | Other Male Genital | Other Respiratory and Intrathoracic Organs | Other Skin | Other Urinary | Ovary | Pancreas | Prostate | Rectum | Small Intestine | Soft Tissue | Stomach | Thyroid | Other Hematopoietic | Phase I | Pediatrics | Unknown Sites | Breast | Cervix | Urinary Bladder
What is the purpose of this trial?
The main purpose of this study is to investigate the safety of LY3405105 in participants with advanced cancer. The study has two parts (A and B). Participants will only enroll in one part.
- Trial withEli Lilly and Company
- Start Date08/05/2019
- End Date05/04/2022
- Last Updated08/13/2020
- Study HIC#2000024397